Pharmacotherapy in SAH: Clinical Trial Lessons

Title:Pharmacotherapy in SAH: Clinical Trial Lessons

Volume: 23 Issue: 11

Author(s): Sotirios Apostolakis*Pantelis Stavrinou

Affiliation:

• Department of Neurosurgery, KAT General Hospital of Attica, Kifisia, Greece
• Department of Neurosurgery, Metropolitan Hospital, Piraeus, Greece

Abstract: Subarachnoid Haemorrhage (SAH) is a medical emergency with potentially devastating outcomes. It is without doubt that over the past decades, there has been a radical change in the approach towards patients with SAH, both in terms of the surgical as well as of the pharmacological treatments offered. The present review aims to outline the principal data regarding the best practice in the pharmacotherapy of SAH, as well as to sum up the emerging evidence from the latest clinical trials. To date, nimodipine is the only evidence-based treatment of vasospasm. However, extensive research is currently underway to identify novel substances with magnesium sulphate, cilostazol, clazosentan and fasudil, demonstrating promising results. Antifibrinolytic therapy could help reduce mortality, and anticoagulants, in spite of their associated hazards, could actually reduce the incidence of delayed cerebral ischemia. The effectiveness of triple-H therapy has been challenged, yet evidence on the optimal regimen is still pending. Statins may benefit some patients by reducing the incidence of vasospasm and delayed ischemic events. As several clinical trials are underway, it is expected that in the years to come, more therapeutic options will be added to the attending physician’s armamentarium.

Cite this article as:

Apostolakis Sotirios*, Stavrinou Pantelis, Pharmacotherapy in SAH: Clinical Trial Lessons, CNS & Neurological Disorders - Drug Targets 2024; 23 (11) . https://dx.doi.org/10.2174/0118715273251761231127095039